{"retracted":false,"update":{"timestamp":1442793600000,"doi":"10.1186/s40064-015-1233-y","type":"correction"},"doi":"10.1186/s40064-015-0827-8","journal":"SpringerPlus","publisher":"Springer Nature","title":"Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations"}
